本文已被:浏览 501次 下载 329次
Received:June 03, 2021 Published Online:February 20, 2022
Received:June 03, 2021 Published Online:February 20, 2022
中文摘要: 糖尿病和心血管疾病两者互为危险因素,严重影响着患者的健康与生活质量。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂是近年来上市的新型降糖药物,多项研究表明其对心血管疾病可能具有保护作用。其保护作用机制是多途径的,主要表现在改善传统的动脉粥样硬化危险因素、利尿利钠、降低尿酸、改善心肌能量代谢、维持心肌细胞钠钙平衡、改善心肌供氧、抗炎和抗纤维化、降低心外膜脂肪组织等。本文就SGLT2抑制剂对心血管疾病的保护作用机制进行综述。
中文关键词: 钠-葡萄糖协同转运蛋白2抑制剂 糖尿病 心血管疾病
Abstract:Diabetes and cardiovascular diseases(CVD) are the risk factors for each other, which seriously affect the health and quality of life of patients. Sodium glucose co-transporter 2 (SGLT2) inhibitor is a new oral hypoglycemic drug listed in recent years and may have a protective effect on CVD demonstrated by many studies. The protective mechanism is mainly built-up in decreasing the traditional risk factors for atherosclerosis, promoting diuresis and natriuresis, reducing uric acid, improving myocardial energy metabolism, maintaining sodium-calcium balance in cardiomyocytes, improving oxygen supply to the myocardium, having anti-inflammatory and anti fibrosis properties and reducing epicardial adipose tissue, etc. This article reviews the protective mechanism of SGLT2 inhibitors against cardiovascular diseases.
文章编号: 中图分类号:R977 文献标志码:B
基金项目:
Author Name | Affiliation |
WU Tao-li, GUO Xing-duan | Department of Endocrinology, the Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524000,China |
Author Name | Affiliation |
WU Tao-li, GUO Xing-duan | Department of Endocrinology, the Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524000,China |
引用文本: